title: Risks and benefits with bevacizumab: evidence and clinical implications.
abstract: With the 1997 filing of an investigational new drug application for the first agent to target angiogenesis, bevacizumab entered into phase I clinical trials and has now become a mainstay in the treatment of several cancers. Bevacizumab has changed the treatment approach for cancers due to its efficacy as well as toxicity. This article serves as a review of current efficacy data including recently published safety analyses and the direction of future pharmacodynamic evaluation to hopefully better guide its utilization.
authors.forename: Carla
authors.initials: C
authors.lastname: Kurkjian
authors.forename: Edward S
authors.initials: ES
authors.lastname: Kim
keywords: bevacizumab; efficacy; pharmacodynamics; safety
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references.pmid: 19720927
references.citation: Am J Hypertens. 2010 May;23(5):460-8
references.pmid: 20186127
references.citation: J Clin Oncol. 2008 Apr 10;26(11):1830-5
references.pmid: 18398148
references.citation: J Clin Oncol. 2011 Jan 10;29(2):142-8
references.pmid: 21135282
references.citation: J Clin Oncol. 2012 May 1;30(13):1534-40
references.pmid: 22454414
references.citation: J Urol. 1997 Jun;157(6):2329-33
references.pmid: 9146665
references.citation: Cancer. 2011 Feb 1;117(3):526-33
references.pmid: 20862750
references.citation: J Clin Oncol. 2009 Jun 20;27(18):3020-6
references.pmid: 19470921
references.citation: Ann Oncol. 2009 Feb;20(2):227-30
references.pmid: 18842611
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4722-9
references.pmid: 17947719
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: J Thorac Oncol. 2010 Sep;5(9):1416-23
references.pmid: 20686429
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references.pmid: 17442997
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3239-47
references.pmid: 20498403
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3523-9
references.pmid: 18640933
references.citation: Cancer. 1997 Jul 1;80(1):98-106
references.pmid: 9210714
references.citation: J Clin Oncol. 2010 May 1;28(13):2144-50
references.pmid: 20368553
references.citation: Ann Surg. 2002 Jun;235(6):759-66
references.pmid: 12035031
references.citation: Int J Cancer. 1996 Jun 21;69(3):205-11
references.pmid: 8682589
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2184-91
references.pmid: 15169807
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3284-9
references.pmid: 19433684
references.citation: N Engl J Med. 2007 Dec 27;357(26):2666-76
references.pmid: 18160686
references.citation: Ann Oncol. 2010 Sep;21(9):1804-1809
references.pmid: 20150572
references.citation: JAMA. 2011 Feb 2;305(5):487-94
references.pmid: 21285426
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2544-55
references.pmid: 15753462
references.citation: J Thorac Oncol. 2011 Jan;6(1):109-14
references.pmid: 21107290
references.citation: Neuro Oncol. 2007 Jan;9(1):29-38
references.pmid: 17108063
references.citation: Urology. 1999 Sep;54(3):523-7
references.pmid: 10475365
references.citation: J Clin Oncol. 2010 Feb 1;28(4):614-9
references.pmid: 19841321
references.citation: Cancer Res. 2001 Mar 15;61(6):2533-6
references.pmid: 11289126
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1227-34
references.pmid: 19188680
references.citation: BJU Int. 2011 Jan;107(2):214-9
references.pmid: 20942831
references.citation: Br J Cancer. 2011 Feb 1;104(3):413-8
references.pmid: 21245868
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5165-71
references.pmid: 18024863
references.citation: J Clin Oncol. 2011 Jan 1;29(1):11-6
references.pmid: 20940184
references.citation: Clin Cancer Res. 2001 Jul;7(7):1932-6
references.pmid: 11448906
references.citation: N Engl J Med. 2003 Jul 31;349(5):427-34
references.pmid: 12890841
references.citation: J Mol Med (Berl). 1999 Jul;77(7):527-43
references.pmid: 10494799
references.citation: Ann Oncol. 2011 Mar;22(3):595-602
references.pmid: 20819780
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5180-6
references.pmid: 18024865
references.citation: Semin Oncol. 1999 Oct;26(5):514-23
references.pmid: 10528899
references.citation: J Natl Cancer Inst. 1998 Mar 18;90(6):447-54
references.pmid: 9521169
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5422-8
references.pmid: 18936475
references.citation: Lancet Oncol. 2010 Aug;11(8):733-40
references.pmid: 20650686
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4286-93
references.pmid: 21990397
references.citation: Cancer Discov. 2011 Jun;1(1):44-53
references.pmid: 22586319
references.citation: J Clin Oncol. 2008 Oct 1;26(28):4672-8
references.pmid: 18824714
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2039-45
references.pmid: 22529265
references.citation: J Clin Oncol. 2011 Apr 1;29(10):1252-60
references.pmid: 21383283
references.citation: Br J Cancer. 2000 Sep;83(5):588-93
references.pmid: 10944597